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ABSTRACT
Background. Low-protein diets are often mentioned but
seldom used to slow chronic kidney disease (CKD) pro-
gression. The aim of the study was to investigate the potential
for implementation of a simplified low-protein diet sup-
plemented with alpha-keto analogues (LPD-KA) as part of the
routine work-up in CKD patients.
Methods. In an implementation study (December 2007–No-
vember 2011), all patients with CKD Stages IV–V not on dialy-
sis, rapidly progressive Stage III and/or refractory proteinuria,
were offered either a simplified LPD-KA, or commercially avail-
able low-protein food. LPD-KA consisted of proteins 0.6 g/kg/
day, supplementation with Ketosteril 1 pill/10 Kg, 1–3 free-
choice meals/week and a simplified schema based on ‘allowed’
and ‘forbidden’ foods. ‘Success’ was defined as at least 6 months
on LPD-KA. Progression was defined as reduction in glomeru-
lar filtration rate (GFR)[(Chronic Kidney Disease Epidemiology
Collaboration) formula CKD-EPI] in patients with at least 6
months of follow-up.
Results. Of about 2500 patients referred (8% CKD Stages IV–
V), 139 started LPD-KA; median age (70 years) and
prevalence of comorbidity (79%) were in line with the dialysis
population. Start of dialysis was the main reason for discon-
tinuation (40 cases, unplanned in 7); clinical reasons were re-
corded in 7, personal preference in 14 and improvement and
death in 8 each. The low gross mortality (4% per year) and the
progression rate (from −8 to 0 mL/min/year at 6 months) are
reassuring concerning safety. None of the baseline conditions,
including age, educational level, comorbidity or kidney func-
tion, discriminated the patients who followed the diet for at
least 6 months.
Conclusions. Our data suggest a wider offer of LPD-KA to
patients with severe and progressive CKD. The promising
results in terms of mortality and progression need confir-
mation with different study designs.
INTRODUCTION
Chronic kidney disease (CKD) is a major health care problem,
and retarding its evolution to end-stage renal disease (ESRD)
has obvious clinical and economic implications [1, 2]. The
first attempts to modulate kidney function via the diet date
back to over a century ago, and the systematic studies of
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Thomas Addis, on which low-protein diets are still extensively
based, were published over 60 years ago [3–5]. In spite of
several trials conducted during the last decade, the role of low-
protein diets remains controversial with discrepancies between
results in intention-to-treat analysis and those in per-protocol
analysis [6–14]. However, it is now usually held that the effect
of a low-protein diet on the progression of CKD becomes
evident only when protein intake is <0.8 g of proteins/kg/day.
Milder regimens may have an effect as ‘metabolic stabilizers’, a
new concept that underlines the clinical and economical
advantages of even relatively small ‘gains’ in a pre-dialysis
phase [15].
A regimen with 0.6 g/kg/day of proteins is often difficult,
unless either a vegan diet (usually supplemented with essential
amino acids and keto acids) is proposed or ‘non-proteic’ (com-
mercially available) carbohydrates are employed; the combi-
nation of both approaches allows protein intakes as low as 0.3
g/kg/day [16–20]. In spite of these problems, a few fundamen-
tal systematic reviews have concluded that the experience with
low-protein diets is generally positive, at least in selected set-
tings [21, 22].
However, low-protein diets are still under-employed and the
main concerns regard their safety and implementation in clini-
cal practice. The comment appearing in The Lancet almost 30
years ago still holds true: ‘The practical implications of these
ideas are enormous, but the time is not yet ripe for generalized,
uncontrolled, application of restricted and unpleasant diets to
patients with renal disease’ [23]. Indeed, several barriers hinder
the application of low-protein diets in CKD patients: they are
often ‘unpleasant and restricted’, impairing long-term compli-
ance; they are difficult to study and they are rather expensive if
they employ ‘non-proteic’ commercial food or keto-acid sup-
plementation [11, 24–27].
Nevertheless, at least three main reasons suggest that the
time is ‘ripe’ for a systematic integration of diet in the clinical
treatment of CKD: the cost of dialysis, the clinical advantages
and the failure of early dialysis to prolong survival. The global
world crisis is challenging all health care systems, and the high
costs of dialysis are central to cost containment [1–2, 28].
Recent studies suggest that the ‘early dialysis’ approaches do
not add to survival, thus underlining the advantages of low-
protein diets not only in slowing the progression of renal
failure, but also as metabolic stabilizers, allowing prolongation
of the ‘pre-dialysis phase’ and ensuring equivalent survival at
lower costs [15, 29–31].
Therefore, the present study was designed to investigate the
potential for implementation of a simplified approach to a
low-protein diet supplemented with alpha-keto analogues
(LPD-KA), with a protein intake of 0.6 g/kg/day, as part of the
routine clinical work-up in non-selected populations of CKD
patients. The study was aimed at answering the question
whether it was possible to identify a profile of ‘ideal patients’
to be prescribed an LPD-KA diet, in keeping with the sugges-
tions in the literature (young, educated and compliant); the
absence of a specific profile would suggest offering a diet trial
to all CKD patients willing to try it.
MATERIALS AND METHODS
Study setting and ‘model of care’
The study was performed in the Outpatient Unit of the Ne-
phrology Unit of San Luigi Hospital, University of Torino,
Italy. The unit started its activity on 1 December 2007. Since
then, about 2500 patients had been evaluated up to 31 March
2012, and about half had been included into our long-term
follow-up. CKD Stages IV–V accounted for about 8% of the
cases. In the study setting, a low-protein diet is proposed by
the nephrologist to patients with CKD Stages IV–V not on
dialysis, with rapid progression of CKD Stage III and/or with
refractory nephrotic syndrome.
Three main therapeutic options are discussed: no diet
(while the policy of our unit strongly supports the use of low-
protein diets, the patient’s choice not to change his/her dietary
habits is also discussed); low-protein diets at 0.6 g/kg/day of
proteins (usually substituting bread, rice and pasta with com-
mercial protein-free carbohydrates); a simplified vegetarian
low-protein diet (0.6 g/kg/day) supplemented with alpha-keto
analogues (LPD-KA). Further options (vegetarian sup-
plemented diets with very low-protein content: 0.3 g/kg/day,
consisting of the simplified LPD-KA plus the substitution of
bread, rice and pasta with commercial protein-free carbo-
hydrates; vegan diet without supplementation, rich in
legumes, according to Barsotti and co-workers) or moderate
reduction of protein intake (0.8 g/kg/day) are discussed in
selected cases.
The simplified LPD-KA, on which the present study is fo-
cussed, derived from the original scheme of Barsotti and Gio-
vannetti [32, 33], is based on a concept of forbidden and
allowed foods (forbidden, except in the context of the free-
choice meal(s): fish, meat, milk, eggs and derivates; everything
else is allowed). The diet is vegan, with an average of 0.6 g/kg/
day protein intake; it is supplemented (Ketosteril 1 cp per 10
kg of body weight, approximated in excess); real weight is con-
sidered for prescription, except in cases with high body mass
index (BMI), where a compromise between real and ideal
weight is individually sought. To improve compliance, 1–3
free-choice meals per week are allowed. The daily energy
intake is aimed at 30–35 kcal/kg/day, but as a rule the foods
are not weighed and the caloric intake is calculated based on a
diet journal after 1–3 weeks. Consultations by the dietician are
given on demand.
Study design and population
This is an observational cohort study. All patients who
started at least a 1-month trial of LPD-KA between 1 Decem-
ber 2007 and 30 November 2011 were included. The physician
extensively discusses the diet; if the patient agrees to test the
LPD-KA diet, 1-month KA supplements are given and the
patient is scheduled for blood tests and clinical visits within 1
month. All the patients considered in the present analysis re-
turned at the 1-month scheduled visit and reported on their
choice to further follow the diet or not; three patients only did
not return for the scheduled visit and were excluded from the
present analysis.
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The follow-up of patients was scheduled as follows: bio-
chemical controls and routine visits are scheduled one per
month; further controls are added in selected cases, up to once
weekly in ‘pre-dialysis’ CKD; follow-up is interrupted at the
start of dialysis. At each visit, patients undergo physical exam-
ination, with particular attention to oedema, and blood
pressure as well as weight measurement.
Data collection
Demographic and clinical data were prospectively gathered
from the start of the diet until its end, and periodically entered
into an electronic database.
Data collected at the start of diet were age, sex, weight,
height, BMI, educational level, comorbidities cause of CKD,
reasons for choice of the diet and previous low-protein diets.
Data collected during the follow-up were cause of death, start
of dialysis and circumstances of initiation (planned or not),
type of dialysis, reasons for dropping out, side effects of diet
and diet compliance.
Compliance is assessed by dietary inquiry and, in stable
patients, by Mitch formula on 24-h urine collection, per-
formed avoiding free meals for the previous 2 days [34]. Fur-
thermore, as the patients receive the keto acids at the clinical
visits, it is possible to calculate the amount of supplements
taken in the period.
We defined dialysis as planned when the start of renal re-
placement therapy was decided timely enough to allow the po-
sitioning of a vascular access (fistula in most of the cases) or a
peritoneal access, without need for hospitalization or acute in-
terventions. In the absence of a sharp GFR cut-point for dialy-
sis start, we took into consideration three major items: water–
salt overload, with oedema and/or severe hypertension; acid–
base imbalance, not corrected by oral bicarbonate; calcium–
phosphate and parathyroid hormon imbalance, once more not
corrected by oral therapy. Ancillary data were refractory
anaemia, or other signs or symptoms of uraemia, such as rest-
less leg syndrome, loss of appetite, weight loss and severe asth-
enia. Even if a specific cut-point was not defined, controls
were intensified <6–7 mL/min of GFR, as a rule from monthly
to twice monthly: treatment of the above-mentioned derange-
ments, common in late CKD stages, is obtained by the usual
means of good clinical practice. The senior nephrologist of the
unit took the final decision on dialysis start.
Biochemical parameters were also collected in the present
study and gathered in the database at start and every 6
months: serum creatinine, urea, creatinine clearance, protei-
nuria and serum albumin. In addition, the following data were
gathered for the subset of patients with at least 6 months of
follow-up: serum bicarbonate, base excess, urinary urea (24-h
urine collection) and bicarbonate supplementation. These par-
ameters were assessed in the laboratory of choice of the
patients; about 70% of the patients performed blood and
urinary tests in the general laboratory of the hospital. GFR was
calculated by Cockcroft and Gault, simplified modification of
diet in renal disease formula and CKD-EPI formulae; the latter
was chosen for GFR calculation in the present analysis, accord-
ing to a growing use of this formula, in particular in the
elderly population [35].
Statistical analysis
A descriptive analysis was performed as appropriate
(median and range in the case of non-parametric data, mean
and standard deviation in the case of parametric distribution).
Analysis of variance, Kruskal–Wallis, Mann–Whitney, χ2 and
t-test were performed according to standard indications. De-
scriptive statistics were done overall, by sex, duration of
follow-up and according to the causes of drop-out.
Mortality rates were calculated as deaths recorded for 100
patient-years of observation.
The ‘gross’ progression rate and dietary compliance were
assessed in a selected subset of cases, allowing contextualiza-
tion of the results; the analysis included the patients with base-
line GFR <60 and >10 mL/min (thus excluding the patients in
which the diet was prescribed for nephrotic syndrome alone),
at least 6 months of follow-up on LPD-KA (the time interval
usually chosen in ‘medium-term’ analysis of LPD-KA), who
started the diet in our unit and who had pre- and post-LPD-
KA renal functional data available, performed in our labora-
tory.
Logistic regression analysis was performed, considering at
least 6 months (and 1 year) of follow-up on the diet as
‘outcome’. The data chosen for dichotomization were the
nearest rounded numbers to the median in our population.
For this analysis, patients who discontinued because of im-
proved kidney function or death were excluded, as were those
in which prescription was done for proteinuria alone (GFR
range at start: 10–60 mL/min).
The ‘forced entry’ method was chosen, due to its simplicity
and to the fact that the stepwise methods fit better when several
covariates prove to be significant at the univariate analysis.
The covariates entered to in the model were chosen either
because of their statistical significance in the univariate analy-
sis [GFR (or creatinine) and proteinuria] or because of their
acknowledged relevance for compliance (educational level),
CKD progression (diabetes, all comorbidities or proteinuria)
and mortality (age, comorbidities and sex), as start of dialysis
and mortality ‘competes’ with a longer duration of the diet.
The following discrete variables were analysed in different
combinations: sex, comorbidity (none and one or more) or
diabetes (present–absent), and educational level (up to eighth
grade, ninth grade and over); the following continuous vari-
ables were analysed: age (dichotomized at 70 years), baseline
creatinine (dichotomized at 3.5 mg/dL) or, alternatively, base-
line GFR (dichotomized at 15 mL/min), baseline proteinuria
(dichotomized at 1 g/day).
The analysis was performed with SPSS (version 18.0). The
results are expressed as odds ratio (OR). The level of statistical
significance was set at <0.5.
RESULTS
Baseline data
The flow chart of the patients who performed at least a
1-month trial of vegetarian LPD-KA is reported in Figure 1
130 patients started the diet in the unit; in addition, nine
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patients previously followed in a different centre resumed
follow-up in our unit; they were all considered in the baseline
analysis. The enrolment rate was relatively homogeneous since
the start of the activity: 31 cases in the first year of study, 36,
36 and 27 in the following years. In another 15 cases, the diet
was prescribed in pregnancy in a dedicated outpatient unit;
three patients continued follow-up in our unit after delivery
and only they were included in the present analysis, two in the
nine patients transferred from another centre and one as new
patient. At the time of the study (at the end of the fourth year
of activity), 56 patients were on the simplified LPD-KA: 54 on
0.6 g/kg/day protein intake and 2 on a ‘very low-protein’ sup-
plemented diet (0.3 g/kg/day).
All the clinical parameters were widely scattered, according
to the heterogeneity of the population and to the broad clinical
indications to the diet (Table 1).
The diet was started or continued in 91 patients with CKD
Stages IV–V (91 started and 9 continued), and started in 29
cases with progressive Stage III CKD and in 10 cases for refrac-
tory proteinuria (CKD Stages I–II).
This is a relatively old population (median age 70), in line
with the median age of 67 of new patients starting dialysis in
our region; as in the European ESRD population, nephro-
sclerosis is the main cause of CKD. Cardiovascular diseases
and diabetes are highly prevalent and represent the main co-
morbid conditions, once more in keeping with the usual fea-
tures of the CKD population (Table 1). No significant
difference in demographic data was found sorting patients ac-
cording to the duration of follow-up (Table 1).
Reasons for discontinuation and side effects of the diet
The main reason for discontinuation of the diet was the
start of dialysis (Table 2). This was planned in 33 (40%)
patients and unplanned in 7 (8%). An unplanned dialysis start
was needed because of an acute cardiovascular accident (myo-
cardial infarction in three cases), an acute infectious problem
(sepsis in three cases), and kidney rupture and massive bleed-
ing in one patient with polycystic kidney disease. Dialysis was
not started in emergency for acute pulmonary oedema or hy-
perkalaemia linked to uncontrolled worsening of CKD in any
patient (Figure 1 and Table 2). Eight patients died (five of car-
diovascular accidents, two of neoplasia and one of sepsis).
Overall gross mortality on the diet was 4.4 cases per 100
patient-years of observation (eight cases over 181 patient-years
on the diet), compared with over 10% in the first year of dialysis
in our area. These mortality data are confirmed also including
in the evaluation the first year of follow up of patients who
dropped-out the diet (included the ones who started dialysis).
Clinical reasons, none of which were severe (gastrointesti-
nal intolerance and/or peripheral oedema), were the cause of
discontinuation in seven (8%) patients. Fourteen (16%)
patients discontinued the diet by their own choice: the reason
was mainly the monotony of the diet and the need for ‘too
many pills’ in addition to the complex polypharmacy. Three of
them shifted from LPD-KA to standard LPDs with commer-
cial products. Seven patients dropped out in the first 3 months
and only one after a long follow-up (97 months). Only three
(4%) patients were lost to follow-up and 3 (4%) continued
their follow-up in another centre.
In eight (10%) patients, the clinical conditions improved
enough to allow discontinuation of the diet. In five cases, clini-
cal improvement was due to optimization of the therapy (focal
segmental glomerulosclerosis starting cyclosporine A, IgA ne-
phropathy treated with prednisone and angiotensin converting
enzyme inhibitors, retroperitoneal fibrosis, obstructive ne-
phropathy and pulmonary neoplasia starting chemotherapy),
while in the remaining three cases the clinical conditions
stabilized after 7–8 months of diet, allowing resumption of a
free-choice dietary regimen (Table 2).
Eighteen patients were counselled by a dietician; the main
reasons were: improvement of compliance, or patient’s
request: seven cases; need for weight loss: four cases; under-
weight: three cases; presence of other relevant clinical pro-
blems potentially interfering with the diet: three cases (active
collagen disease, Chron’s disease and liver disease) and need
for adaptation of Ayurveda diet: one case.
Progression of kidney disease
In the subset of cases analysed, the median GFR decrease
was −4 mL/min/6 months (corresponding to −8 mL/min/
year) before starting the diet, and kidney function decreased
less steeply and stabilized in the cases who ‘remained on the
diet’; the wide range of kidney functional data has to be under-
lined (Figure 2 and Table 3). The median progression (loss of
GFR) was not modified in the patients who dropped out in the
first 6 months (median GFR decrease: −10 mL/min/year), and
the value decreased to −6 mL/min/year in the patients who
dropped out after 6–12 months. Albumin and total protein
levels remained stable throughout the study period (Table 3).
The median HCO3 at 6 months was 26.5 mmol/L (range
18.8–34.4 mmol/L), with base excess 1.45 (range −7/+12); 20
patients were not on oral bicarbonates at start and did not
need them after 6 months of diet; 20 continued the sup-
plementation, 6 started it, 1 reduced the doses and 1 discontin-
ued it.
In the same selected subset of stable patients, according to
the Mitch formula, at 6 months, median protein intake was
0.5 g/kg/day (range 0.34–0.71 g/kg/day).
F IGURE 1 : Flow chart of patients who started vegetarian LPD-KA.
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Table 1. Baseline data: all patients with at least a 1-month trial are considered
All patients
(139)
Males (93) Females (46) P-
value
Follow-up ≤1
month (22)
Follow-up 2–5
months (22)
Follow-up ≥6
months (95)
P-
value
Males/females 66.9% – – – 63.6% 72.7% 66.3% ns
Age median (range) 70 (27–91) 70 (27–91) 69.5 (30–88) ns 69.5 (30–84) 72 (53–85) 69 (27–91) ns
Educational level
(>eighth degree)
51.9% 62.4% 23.9% <0.001 47.1% 68.2% 48.9% ns
BMI median (range) 26.1 (16.3–
44.9)
26.1 (16.3–
35.9)
27.3 (16.8–
44.9)
ns 26.7 (16.8–44.9) 25.8 (19.5–35.9) 26.1 (16.3–43.0) ns
Renal disease
Glomerulonephritis
(%)
19.4 23.7 10.9 0.02 18.2 13.6 21.1 ns
Diabetic
nephropathy (%)
17.3 12.9 26.1 0.02 9.1 4.5 22.1 ns
Nephrosclerosis
(%)
35.3 37.6 30.4 ns 45.5 50 29.5 ns
Serum creatinine at
start median (range)
3.2 (0.8–16) 3.4 (0.8–16) 3.0 (1.3–10) ns 3.12 (1.7–16) 3.77 (1.88–6.67) 3.0 (0.87–6.7) 0.05
GFR at start (CKD-
EPI) median (range)
17 (3–110) 17 (3–110) 16 (5–48) ns 17 (3–44) 13.5 (7–37) 17.5 (8–110) 0.05
Proteinuria 24 h at
start median (range)
1.4 (0–18) 1.75 (0–18) 0.9 (0–8.9) 0.045 1.25 (0–17.8) 1.6 (0–18) 1.4 (0–10.4) ns
Diabetes (%) 40.3 38.7 43.5 ns 27.3 36.4 44.2 ns
Cardiovascular
comorbidity (%)
41.7 47.3 30.4 ns 45.5 54.5 37.9 ns
Neoplasia (%) 19.4 25.8 6.5 0.013 9.1 31.8 18.9 ns
No comorbidity (%) 20.9 16.1 30.4 ns 18.2 13.6 23.2 ns
≥2 comorbid factors
(%)
45.3 47.3 41.3 ns 36.4 63.6 43.2 ns
P-values were calculated by: χ2 test, Kruskal–Wallis test and Mann–Whitney U-test.
A renal biopsy was performed in 11 diabetic patients (two with diabetic nephropathy and nine with other kidney diseases); and in the other cases, diabetic nephropathy was defined by a
‘classic clinical course’ with intense proteinuria, consensual target organ lesions and no evidence of other renal diseases.
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Prediction of follow-up of at least 6 months on the diet
Table 4 reports the results of the multivariate analysis, con-
sidering ‘success’ as a duration of the diet of at least 6 months.
None of the tested parameters, including age, sex, educational
level and comorbidity, was predictive of ‘success’ of the diet,
thus failing to identify the elements for an a priori definition
of a profile of CKD patients in which a LPD-KA is likely to be
followed for a relatively long time. The results were confirmed
when serum creatinine (dichotomized at 3.5 mg/dL) was con-
sidered instead of GFR and also, in the smaller subset of cases
who started the diet before November 2010, when the pre-
scription ‘success’ was set at 1 year.
DISCUSSION
The present implementation study was aimed at testing our
simplified approach to a LPD-KA (protein intake of 0.6 g/kg/
day) in patients with severe or progressive CKD referred to a
new nephrology unit. Flexibility starts from prescription, as
the diet is simply based on allowed and forbidden foods,
without the need to weigh all foods; 1–3 free-choice meals are
allowed to reduce the psychological burden and to avoid mal-
nutrition. The diet is initially proposed as a 1-month trial and
is prescribed and controlled by the nephrologist in the context
of the routine clinical follow-up. This schema was developed,
following a few pilot experiences in smaller subsets of patients,
on the hypothesis that a simplified approach using a ‘not-too-
strict’ diet (0.6 g/kg/day of proteins) was feasible and could
provide positive results with a low risk of side effects [36, 37].
The subset of cases who started the LPD-KA diet was in
line with the population starting dialysis in our region in
terms of age (median 70 years) and high prevalence of dia-
betes, nephrosclerosis and multiple comorbidities (Table 1).
The enrolment rate on the diet was relatively high; about 5%
of all patients followed in our unit experienced at least one
trial of LPD-KA and the figure rose to over 30% of the referred
patients with CKD Stages IV and V.
An interesting suggestion of our study, needing confir-
mation on a larger scale, with higher statistical power, is the
lack of strong clinical and demographic elements for an a
priori definition of ‘good’ candidates for LPD-KA, considering
‘prescription success’ as at least 6 months of follow-up
(Table 4). It is noteworthy that educational level (often associ-
ated with higher compliance), diabetes, overall comorbidity
(often associated with poor dietary compliance) and old age
(frequently considered to impair efficient modulation of the
diet) are not confirmed as strong relevant factors in attaining
the medium-term follow-up of the diet, at least in this rela-
tively small population.
Interestingly, at least in stable patients with at least 6 months
of follow-up, compliance was impressive, with a median protein
intake of 0.5 g/kg/day, calculated at distance from the free meals.
This supports the hypothesis that subtle personal preferences, as
well as clear motivations, are fundamental in the relationship
with food and diet. Therefore, the diet should be proposed to all
patients without preclusion (Table 4).
In view of the main finding, our study prompts several
further observations worth discussing. Possibly because of the
flexible policy, the allowance of free-choice meals and the
strict control policy, there were few clinical reasons for discon-
tinuation, and no case of malnutrition was recorded as a cause
of discontinuation. Conversely, psychological reasons for
dropping out were more common, underlining the strong
negative effect of monotony of the dietary regimen and the
need for several ‘pills’, usually in the context of a complex
polypharmacy (Table 2). The start of dialysis was the main
cause of discontinuation of the diet (Table 2). In this series, all
the patients who needed unplanned dialysis experienced acute
clinical problems, related more to the clinical conditions than
to the diet and the advanced CKD; this subset of patients
F IGURE 2 : Graphical representation of the value of GFR-EPI for each patient. Filled triangle: last update before death; filled circle: last update
before dialysis start; filled square: median GFR-EPI and trend.
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Table 2. Reasons of discontinuation: all patients
Death (8) Planned
dialysis start
(33)
Un-planned
dialysis start
(7)
Patient’s
choice (14)
Clinical
reasons (7)
Improved (8) Lost to
follow-up—
transferred to
another
centre (6)
On the diet at
30 November
2011 (56)
P-
value
Age median
(range)
74.5 (57–86) 66 (30–85) 70 (35–76) 64 (43–79) 74 (59–81) 75.5 (49–88) 72.5 (31–84) 69.5 (27–91) 0.39
Educational
level >eighth
degree (%)
25 60.6 42.9 71.4 28.6 25 50 54 0.21
Serum
creatinine at
start median
(range)
3.2 (2.08–5) 4.6 (2.9–16) 3.5 (1.7–6.2) 2.5 (1.2–5.5) 2.2 (1.8–5.1) 2.8 (1.7–5.0) 3.4 (2.9–3.9) 2.8 (0.8–6.7) <0.001
GFR at start
(CKD-EPI)
median
(range)
16 (8–28) 11 (3–20) 11 (8–41) 23 (10–67) 27 (9–31) 17 (12–40) 19 (11–25) 20 (8–110) <0.001
Proteinuria
24 h median
(range)
0.2 (0–1.5) 2.15 (0.2–18) 1.5 (0.8–4.6) 1.6 (0–10.4) 0.7 (0.3–4.7) 0.5 (0.1–4.5) 2.75 (0.7–4.9) 1.4 (0.1–8.2) 0.01
No
comorbidity
(%)
0 21.2 14.3 14.3 14.3 25 50 23.2 0.51
≥2 comorbid
factors (%)
87.5 36.4 71.4 35.7 71.4 37.5 33.3 42.9 0.10
P-values were calculated by: χ2 test and Kruskal–Wallis test.
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Table 3. Main data at the intervals considered and main GFR loss, in patents with at least 6 months of follow-up and data available in
our laboratory
−6 months
(49 cases)
Start (82 cases) +6 months (60 cases) +12 months (46 cases) +18 months (38 cases)
All cases with at least 6 months of follow-up (data from the same laboratory)
GFR-EPI (mL/min) 25 (10–63) 18.50 (10–58) 20 (7–75) 21 (6–69) 19 (4–75)
Total proteins (g/dL)
7.20 (5.3–8.5) 6.90 (4.1–8.6) 7.20 (4.6–8.4) 6.80 (5.1–8.9) 6.90 (5.3–7.9)
Albumin (g/dL) 3.71 (1.9–4.5) 3.80 (1.4–4.8) 4.00 (1.8–4.9) 4.14 (2.8–5.4) 3.70 (2.4–4.7)
−6 months to start (48 cases) 0–6 months (48 cases) 6–12 months (34 cases) 12–18 months (28 cases)
Only patients with at least 6 months of follow-up, who started in the unit, with available data in our laboratory before and after the start of the diet
Loss of GFR
(mL/min/6 months):
−4 (−25 to +19) 0 (−13 to +20) −3 (−13 to +15) −1 (−7 to +7)
GFR-EPI at the
interval (mL/min)
25 (10–63) 19.50 (11–58) 20 (7–75) 22 (8–69) 20.50 (4–75)
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shared higher age and prevalence of comorbidities with the
patients who died while continuing the diet (Table 2).
The low mortality rates (4.4 cases per 100 patient-year),
within the limits of relatively small numbers and short follow-
up, give further reassurance that there is no negative impact of
LPD-KA in our population; our data are in the same line of
other reports of long-term safety of LPD-KA, as the important
long-term analysis of the French school, regarding patients
treated by very low-LPD-KA, observed after the start of dialy-
sis [17].
Our study was neither designed nor sufficiently powerful to
demonstrate an effect on the progression of CKD. Routine lab-
oratory data, such as creatinine clearance, lack the precision of
isotopic or inulin clearances. Within these limits, the analysis
of the progression rate (performed to allow contextualization
of our results), suggest that at least patients with longer follow-
up may stabilize on the LPD-KA diet, an issue to be confirmed
on larger numbers and longer follow-up (Table 3).
In this regard, even a small delay of dialysis is potentially
highly favourable in terms of costs. In our area, 1 year of dialy-
sis corresponds to 35–60 patient-years on LPD-KA, based on
the regional data indicating the costs of dialysis to be 35–
60 000 Euros per year and assuming that the costs of the LPD-
KA correspond to the supplements, averaging 1000 Euros per
year (0.4 Euros per pill, 8 pills per day, 330 days per year) [38].
This analysis has some strong points: it demonstrates that
LPD-KA is feasible outside of the few large referral centres
where much of the experimental data have been collected, at
least in a relevant percentage of patients with severe CKD. The
low drop-out rate (not considering clinical improvement,
death and start of dialysis, as the diet is aimed at prolonging
dialysis-free survival) is in keeping with this observation. It
underlines the importance of the ‘patient effect’ in the choice of
the diet, thus arguing against the often-held conception that
LPD-KA is too difficult ‘for the patients’. It also demonstrates
that a relatively ‘soft and flexible’ LPD-KA (0.6 g/kg/day, with
1–3 free-choice meals per week) may become part of the clinical
nephrology routine, in keeping with a long-lasting experience of
diet management by nephrologists [3, 9, 15, 19, 28, 32, 33].
Last but not least, it adds some mortality data, suggesting
that the low mortality rates (4.4 per 100 patient-years) may be
taken as an indication of the safety of LPD-KA.
Our study also has several shortcomings, partly shared with
similar study designs. Implementation studies are not ran-
domized and thus are more apt to define practical strategies
than to assess treatment efficacy [39, 40]. This suggests that
our favourable data on progression and mortality should be
considered only indicative and as a stimulus for further analy-
sis. Even more importantly, a control group of patients who
choose either no diet or a different LPD (for example with
commercial food) was not available for the present analysis;
such an analysis is planned in the context of a perspective
study, including all CKD Stage IV–V patients followed in our
unit. The number of cases is still limited, in particular after the
selections needed for statistical analyses. However, this limit is
shared by several studies dealing with clinical practice, in
which the quality of data may differ from randomized trials;
indeed, in the last decade, a few series report on over 100
patients on LPD-KA, with a range from a few cases in short-
term metabolic assessments (16 on LPD-KA a recent
Table 4. Logistic regression analysis, considering a follow-up on the diet of at least 6 months as
outcome
N = 100 Number in group Follow-up ≥6 months OR 95% CI
Age <70 47 37
Age ≥70 53 38 0.71 0.22–2.29
Females 34 26
Males 66 49 1.57 0.44–5.55
Educational level up to the eighth grade 46 36
Educational level above the eighth grade 53 38 0.41 0.12–1.43
Diabetes (absence) 60 43
Diabetes (presence) 40 32 1.59 0.55–4.64
No comorbidity 21 18
Presence of at least one comorbidity 79 57 0.13 0.01–1.27
GFR-EPI <15 mL/min 40 27
GFR-EPI ≥15 mL/min 59 48 1.99 0.69–5.66
Proteinuria <1 g/day 34 25
Proteinuria ≥1 g/day 60 48 1.44 0.49–4.23
For this analysis, patients who discontinued because of improved kidney function or death were excluded, as were those in which
prescription was done for proteinuria alone (GFR range at start: 10–60 mL/min).
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randomized controlled trial by Di Iorio) to 203 in the large
French study on the outcome of dialysis of patients previously
treated by very low-LPD-KA for at least 3 months [22, 36, 41].
Within these limits, our data support a wider use of LPD-
KA as an option to be offered to all patients with advanced or
progressive CKD. Further studies are needed to assess the
clinical (in particular as for mortality rates) and economic
advantages of LPD-KA, also taking into account the support
therapies and the indications for dialysis, and to confirm the
feasibility of our simplified dietary programme in different
clinical settings.
CONCLUSIONS
The data obtained in this feasibility study may support a wider
offer of LPD-KA to patients with severe and progressive CKD,
as ‘success’ of at least 6 months on the diet can be obtained in
elderly patients with high comorbidities and low educational
level, further underlining the importance of individual choices
and empowerment in CKD patients. Such a dietary pro-
gramme is feasible, safe and adaptable to a routine clinical
setting, and it can provide promising results in terms of
slowing the progression of CKD, even though these results
must be confirmed by studies using control groups and explor-
ing its implementation in different clinical settings.
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Piccoli and colleagues in Italy report on the tolerability, impact
and outcomes of CKD4-5 patients (139) given a low protein diet
(LPD) (0.6g/kg/day) supplement with keto-analogues (Ketosteril)
compared to a standard LPD. They imply from their observation
that such promising results on CKD progression and low mor-
tality (4%/year) should encourage more to prescribe such a diet
to patients with advanced renal insufficiency.
This observational cohort study is a throw back to the 70-
80s when such diets including those with a very low in protein
content (0.3g/kg/day) were prescribed to patients with ad-
vanced renal insufficiency, mainly by Italian Nephrologists to
delay the onset of dialysis.
Since, a group of like-minded nephrologists came to the
"final" conclusion that such diets are potentially beneficial [1].
The validity of their argument remains to be tested! In The
UK, such diets are seldom recommended.
(1) Are Italian nephrologists still prescribing LPDs to
patients with CKD4-5, in spite of the negative result of
the MDRD largest randomized controlled study pub-
lished in 1994 [2]?
(2) How can CKD progression be evaluated on such diets
with serum creatinine, creatinine clearance or creatinine
derived equations knowing that such diets impact on cre-
atine intake, metabolism, stores as well as urinary
excretion? This is a point acknowledged by the authors,
but of concern to the NDT OLA readers as such diets
give the subjective impression of functional improvement
and delay of the onset of ESRD and RRT when in reality
they alter an inappropriate surrogate marker for CKD,
namely serum creatinine, under such dietary prescrip-
tion! This brings back my old Lancet review highlighting
10 unanswered question with LPD….[3]. Although
these questions, were challenged by Fouque and Aparicio
by 11 arguments… as to why such diets should be pre-
scribed [4]. I remain unconvinced!
(3) What is the true risk:benefit and cost:benefit analyses of
such diets in terms of nutritional status and outcomes
when compared to a free protein intake which is known to
be spontaneously reduced in advanced renal insufficiency ?
(4) Finally, how can such dietary protein restrictions be justi-
fied in low and middle economies where undernutrition
is a feature of ESRD?
Prof Meguid El Nahas
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